PRAX Praxis Precision Medicines Inc

$PRAX Finally pulled the trigger on PRAX and loaded up on this dip. I respect several of the bullish analysts who feel this is a winner. Waiting to buy was not easy, although I bailed on $JAZZ before it dipped. I like both, but went risk-on today with PRAX.

$PRAX Ulixacaltamide was granted breakthrough therapy designation by the FDA. To get BTD, early clinical trials must demonstrate that the drug offers a major improvement over existing treatments.

$PRAX (Praxis Precision Medicines) gets its price target raised to $534 from $441 by JonesTrading, which maintains a Buy rating, citing progress in the company's late-stage central nervous system drug pipeline.

$PRAX Now 3 months until Relutrigine PDUFA date, December 27, 2026. Relutrigine holds Priority Review, Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations from the FDA.

$PRAX As a follow-up to the EMBOLD study, in which PRAX treated SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients with Relutrigine, PRAX is currently conducting the broader EMERALD clinical trial. EMERALD is testing Relutrigine across more than 50 distinct genetic etiologies of DEEs. PRAX surpassed their EMERALD enrollment goal of 160 patients, enrolling approximately 200 patients. The topline readout of EMERALD is expected to occur in Q4, 2026. Since clinicaltrials dot gov (NCT07010471) indicates primary completion in DEC 2026, we can expect the read out to occur in December. If the results are good, PRAX plans to submit an sNDA to the FDA for broad DEE approval of Relutrigine.

$PRAX Following up with the relutrigine SCN2A- and SCN8A-DEE (developmental and epileptic encephalopathy) EMBOLD trial, Praxis is running their EMERALD trial. EMERALD is a broader trial of relutrigine across more than 50 distinct genetic etiologies of DEEs. PRAX exceeded their initial enrollment target of 160 patients in the EMERALD studt, enrolling approximately 200 patients. Topline results are expected to be read out in the fourth quarter of 2026 and, if positive, could support a supplemental NDA submission in 2027.

$PRAX building a sizable position here of 1500 shares plus looking for similar outcome as I experienced with APGE getting eaten up by ABBV rocket 🚀 here much higher!

$PRAX this is going to be the biggest bust we have seen in a while. An ET drug that if approved will cost 50k for a condition that can be cured by a procedure that costs far less and a one time treatment. And the approval is a big if. Side effects. Moved endpoints. Few responders. Unclear durability. The seizure drug has more potential but market cap won’t hold because they are expecting the ET program to tow this turd of a company.

$PRAX autumn great time here in New England it is time to start lighting the candles and I think i will burn the red ones first. Green balsam is perfect for Christmas. Shopping early is great fun I think should do an add for yankee candles and have fidelity endorse it.

$PRAX does anyone know why this keeps dropping? Awfully strange for a company with 2 PDUFAs just a few months away.

$PRAX watching this for starting a long term position. Thankful they are researching SCN2A. My daughter has LoF (thankfully) and it is such a rare condition. Wanted to short the 370s, but morally I can only hope for their success for families like mine. Let's goooooo 💪

$PRAX The ultrasound treatment has been around for a decade and has not solved the problem — still millions of patients. The cost is $60,000 for two sides. Ulixa price is not set and flexible, manufactuting cost is very low and even at $2,000 a year it's going to be a multibillion dollar product.

Needham & Company named five biotech stocks among its top picks, maintaining Buy ratings across the group as several companies approach key clinical readouts in the second half of 2026. Catalysts range from Phase 3 epilepsy data to potential results in Alzheimer's-related psychosis. Praxis Precision Medicines is one of Needham's highest-conviction picks, with a $582 price target. Despite limited momentum in the first half following the POWER1 trial failure and a delay to the PDUFA date for relutrigine in DEE associated with SCN2A/SCN8A mutations, Needham expects the stock to regain momentum with the upcoming Phase 3 EMERALD readout in the broader DEE population. Treatment options for these patients remain limited, with Lundbeck's bexicaserin representing the other major development program expected to produce Phase 3 data in late 2026 or early 2027. The EMERALD study is enrolling a severely affected population with more than 50 countable seizures per 28 days at baseline. $PRAX

$PRAX going to be reading more into this one.. some top analysts see massive upside here.

$PRAX There is meaningful short interest. As of Aug. 31, about 3.74 million shares, or 13.8% of the float, were short, with roughly 10.2 days to cover. That's substantial and can amplify moves in either direction. Relutrigine: PDUFA December 27, 2026 Ulixacaltamide: PDUFA January 29, 2027